Picovir “not approvable” letter
ViroPharma expects to receive a "not approvable" letter for cold treatment Picovir by May 31. Results of Phase I studies of the picornavirus treatment's interaction with oral contraceptives and the duration of the related CYP3A enzyme induction are expected this summer. ViroPharma and marketing partner Aventis "will work together to determine what further action will be taken with Picovir," ViroPharma says. FDA's Antiviral Drugs Advisory Committee voted not to recommend the product for approval March 19 (1"The Pink Sheet" March 25, p. 31)...
You may also be interested in...
Viropharma expects to have data from a Phase I drug interaction study of oral contraceptives and Picovir (pleconaril) in two to four months
BVMed says the EU and the UK should set up a system of mutual recognition of medical device regulation to kick in when the UK’s EU exit transition period ends on 31 December.
HER3 may be a new target for anticancer antibody-drug conjugates; clinical investigators posted promising early stage clinical results with Daiichi Sankyo’s HER3 targeting antibody-drug conjugate, patritumab deruxtecan, at the recent ESMO virtual meeting.